TSC1-Related Tuberous Sclerosis Complex: Disease Characteristics Research Report

Scope and evidence note

This report treats Tuberous Sclerosis 1 as the molecular subtype of tuberous sclerosis complex (TSC) caused by a pathogenic TSC1 variant. Most diagnostic, epidemiologic, surveillance, and therapeutic evidence is reported for combined TSC1/TSC2 cohorts; where evidence is specifically TSC1-stratified, that distinction is stated. The principal current authority is the 2021 International TSC Consensus guideline (published October 2021; DOI: https://doi.org/10.1016/j.pediatrneurol.2021.07.011). Recent sources prioritized include 2023–2024 molecular, single-cell, clinical-practice, and trial data.

Table: This table condenses the most knowledge-base-ready facts for TSC1-related tuberous sclerosis complex, including identifiers, genetics, mechanisms, phenotypes, surveillance, treatment, and model systems. It emphasizes ontology-friendly mappings and quantitative evidence from consensus guidelines, recent studies, and active clinical trials.

1. Disease information

Definition

TSC1-related TSC is a congenital, autosomal-dominant, multisystem tumor-predisposition and neurodevelopmental disorder caused by loss of hamartin-mediated restraint of mTOR complex 1 (mTORC1). It produces hamartia and usually benign hamartomas in brain, skin, kidney, heart, lung, and retina, together with epilepsy and TSC-associated neuropsychiatric disorders (TAND). A useful recent abstract description is: “Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and multisystem disease caused by pathogenic DNA alterations in the TSC1 and TSC2 tumor suppressor genes.” (Dufner-Almeida et al., published 3 November 2024; DOI: https://doi.org/10.3390/genes15111432). (dufneralmeida2024molecularandfunctional pages 1-2)

Identifiers and synonyms

• MONDO: MONDO:0008612, tuberous sclerosis 1; broader TSC is MONDO:0001734. Open Targets links MONDO:0008612 to TSC1, Ensembl ENSG00000165699. (OpenTargets Search: tuberous sclerosis 1,tuberous sclerosis complex-TSC1)
• OMIM: disease commonly indexed as Tuberous sclerosis-1 / TSC1, OMIM 191100; gene TSC1, OMIM 605284. The retrieved molecular paper explicitly confirms MIM 605284 for TSC1. (dufneralmeida2024molecularandfunctional pages 1-2)
• MeSH: Tuberous Sclerosis, D014402. (NCT05534672 chunk 1)
• ICD-10-CM: Q85.1, Tuberous sclerosis.
• ICD-11: LD2D.0, Tuberous sclerosis.
• Orphanet: ORPHA:805, Tuberous sclerosis complex.
• Common names: tuberous sclerosis complex, TSC, Bourneville disease, Bourneville–Pringle disease, epiloia, TSC1-related TSC.

The evidence is predominantly aggregated disease-level evidence from consensus guidelines, registries, cohorts, trials, and laboratory studies. The 2024 Japanese diagnostic-flow study is EHR-like administrative evidence derived from health-insurance claims, whereas TOSCA is an international disease registry. Individual case reports are informative for unusually mild or mosaic phenotypes but should not define population frequencies.

2. Etiology, risk, protective factors, and gene–environment interaction

Primary causal factor

The necessary initiating cause is a heterozygous pathogenic or likely pathogenic TSC1 alteration. TSC1 lies at 9q34.1, comprises 23 exons, and encodes hamartin. Hamartin stabilizes the TSC protein complex containing TSC2/tuberin and TBC1D7. The complex acts as a GAP for RHEB; its loss increases RHEB-GTP, mTORC1 kinase activity, S6K phosphorylation, anabolic metabolism, and cell growth. (zucco2018thegenerationand pages 35-40, dufneralmeida2024molecularandfunctional pages 1-2)

Lesions frequently follow tumor-suppressor two-hit biology: a constitutional or mosaic first hit is followed by somatic inactivation of the remaining allele. This is strongly supported in renal, cutaneous, pulmonary, and other tumors, although a demonstrable second hit is inconsistent in cortical tubers; haploinsufficiency, low-level cell-restricted second hits, and non-cell-autonomous signaling may all contribute to brain disease. (zucco2018thegenerationand pages 40-44, man2024thegeneticsof pages 8-9)

Genetic risk factors

• A pathogenic germline TSC1 variant confers high, age-dependent penetrance but markedly variable expressivity.
• De novo and postzygotic mosaic variants are common contributors. Approximately two-thirds of all TSC is sporadic/de novo and one-third familial, although proportions vary by ascertainment. (man2024thegeneticsof pages 1-2)
• Higher accessible-tissue mosaic variant allele fraction sometimes correlates with more clinical features, but studies are inconsistent. One 2024 review reports median VAFs of 7.74% for mosaic TSC1 versus 1.93% for mosaic TSC2 and notes a proposed—but unvalidated—possibility that TSC1 VAF below 3% in blood/saliva may be less likely to satisfy clinical criteria. (man2024thegeneticsof pages 8-9)
• Compared with TSC2, TSC1 disease is, on average, milder, with later/smaller renal angiomyolipomas and less severe epilepsy; this is a population tendency, not a reliable individual prognosis. (pratico2025geneticscreeningof pages 8-9, kingswood2020renalmanifestationsof pages 1-2)
• No reproducibly validated modifier gene currently supports routine clinical risk prediction. Variation in second-hit timing, lineage, tissue distribution, variant type, residual complex function, and mosaic fraction likely explains substantial variability.

Environmental and lifestyle factors

There is no established toxin, infection, diet, occupation, smoking exposure, or lifestyle behavior that causes Mendelian TSC1-related TSC. Environmental factors instead modify complications:

• Smoking and exogenous estrogen are clinically relevant concerns in pulmonary LAM; patients should avoid smoking, and estrogen-containing therapy requires individualized pulmonary assessment.
• Pregnancy may accelerate angiomyolipoma or LAM-related risk through hormonal and hemodynamic effects; this is complication modification, not disease causation.
• CYP3A4/P-glycoprotein inducers or inhibitors, infections, surgery, diet, and adherence alter mTOR-inhibitor exposure and safety.
• Sleep deprivation, fever, and missed medication can lower seizure threshold but do not create TSC lesions.

No proven genetic protective allele or environmental intervention prevents TSC after conception. Lower mosaic burden and TSC1 rather than TSC2 genotype are associated with milder average expression, but are not actionable protective factors. The strongest practical “protection” is secondary prevention through surveillance and early treatment.

3. Phenotypes

Neurologic and neurodevelopmental

• Epilepsy—symptom/clinical sign; usually infancy or early childhood, episodic and often progressive toward drug resistance. Consensus data indicate focal seizures or epileptic spasms in 63–78% of infants. In a TSC1-specific Sicilian cohort, epilepsy occurred in 64.5%, with mean onset 35.4 months; 35% were drug resistant. Suggested HPO: Seizure, Focal-onset seizure, Epileptic spasm, Drug-resistant epilepsy. (pratico2025geneticscreeningof pages 3-4, northrup2021updatedinternationaltuberous pages 10-14)
• Cortical tubers and radial migration lines—congenital imaging/pathology signs, structurally stable but epileptogenic consequences evolve. TSC1 cohort frequencies were 67.8% for cortical tubers and 51.6% for subependymal nodules. HPO: Cortical tuber, Radial migration line, Subependymal nodule. (pratico2025geneticscreeningof pages 3-4)
• SEGA—usually childhood/adolescence; may enlarge and cause hydrocephalus, headache, vomiting, visual change, or behavioral deterioration. Reported in up to 24% in broad TSC cohorts. HPO: Subependymal giant cell astrocytoma, Hydrocephalus. (cockerell2023effectivenessandsafety pages 1-2)
• TAND—behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial abnormalities, collectively affecting approximately 90% across TSC literature. In the cited TSC1 cohort, ASD was 12.9%; cognition was normal in 51.6% and severely impaired in 16.1%. Severity ranges from subtle school difficulties to profound disability. Suggested HPO: Intellectual disability, Autism, Attention deficit–hyperactivity disorder, Anxiety, Depressive disorder, Sleep abnormality, Aggressive behavior. (pratico2025geneticscreeningof pages 3-4, singh2023treatmentresistantepilepsyand pages 1-3, northrup2021updatedinternationaltuberous pages 10-14)
• White-matter/hypomyelination abnormalities—imaging and tissue sign; associated with altered neural connectivity, cognition, and ASD. Both oligodendrocyte-autonomous mTOR dysregulation and abnormal neuron–glia signaling are implicated. HPO: Abnormal cerebral white matter morphology, Hypomyelination. (zimmer2020tuberoussclerosiscomplex pages 6-7)

Renal

• Renal angiomyolipoma (AML)—imaging/structural manifestation, commonly bilateral and multiple; prevalence and size rise with age. TOSCA recorded AML in 1,062/2,211 (48%), median diagnosis age 13 years. Females had more lesions, lesions >3 cm, growing lesions, and interventions. TSC1 lesions arose later and were smaller/less often growing on average, but by age 40 the proportion needing intervention did not differ clearly from TSC2. HPO: Renal angiomyolipoma, Renal hemorrhage. (kingswood2020renalmanifestationsof pages 1-2)
• Renal cysts, hypertension, declining GFR/CKD, and uncommon renal-cell carcinoma are important lifelong complications. HPO: Renal cyst, Hypertension, Chronic kidney disease, Renal cell carcinoma.

Skin, dental, eye, heart, and lung

• Hypomelanotic macules may be congenital; shagreen patches, fibrous cephalic plaques, facial angiofibromas, and ungual fibromas appear from childhood onward and may progress. HPO terms: Hypopigmented skin macule, Facial angiofibroma, Shagreen patch, Ungual fibroma, Fibrous cephalic plaque.
• Dental enamel pits and intraoral fibromas are usually chronic signs. HPO: Dental enamel pits, Oral fibroma.
• Retinal astrocytic hamartoma and achromic retinal patch are often asymptomatic/stable but can impair vision. HPO: Retinal hamartoma, Retinal hypopigmentation.
• Cardiac rhabdomyoma is often prenatal/neonatal, may obstruct flow or cause arrhythmia, and usually regresses. In a Japanese claims cohort diagnosed before age two, rhabdomyoma was the most frequent initial manifestation, at 54.8%. HPO: Cardiac rhabdomyoma, Cardiac arrhythmia. (man2024thegeneticsof pages 1-2)
• TSC-LAM—progressive cystic lung disease, predominantly in adult females. It occurs in about 30–40% of adult females with TSC; pneumothorax occurs in up to 70% of patients with LAM. HPO: Lymphangioleiomyomatosis, Cystic lung disease, Pneumothorax, Dyspnea, Chylous effusion. (jansen2020burdenofillness pages 1-2)
• Multifocal micronodular pneumocyte hyperplasia is usually stable and clinically mild. HPO: Multifocal micronodular pneumocyte hyperplasia.

Quality-of-life impact

TOSCA’s 143-person QoL substudy found education/career impairment in 42.1% of patients, family-life/social/work effects reported by 76.5% of caregivers, pain/discomfort in 35%, and anxiety/depression in 43.4%. Only 36.8% of adults described a smooth pediatric-to-adult transition. (jansen2020burdenofillness pages 1-2)

A 2024 German matched study found adults with TSC epilepsy had EQ-5D-3L utility 0.705 and VAS 0.577, 60% unemployment, and markedly higher direct and productivity costs than matched idiopathic generalized or focal epilepsy groups. These burden estimates apply to TSC epilepsy overall, not specifically TSC1.

4. Genetic and molecular information

Gene and variant classes

• TSC1: HGNC symbol TSC1; Ensembl ENSG00000165699; OMIM 605284; chromosome 9q34.1; protein hamartin, RefSeq NP_000359.1. (OpenTargets Search: tuberous sclerosis 1,tuberous sclerosis complex-TSC1, dufneralmeida2024molecularandfunctional pages 1-2)
• Disease mechanism: loss of function, primarily haploinsufficiency plus lesion-specific second hit.
• Pathogenic classes: nonsense, frameshift, canonical splice, exon/multiexon deletion, whole-gene deletion, duplications disrupting the reading frame, deep-intronic splice variants, and functionally established missense/in-frame variants.
• A TSC1-specific cohort reported intragenic deletions 48.4%, nonsense 38.7%, missense 9.6%, and duplication 3.2%, but this regional sample should not be treated as a universal spectrum. (pratico2025geneticscreeningof pages 3-4)
• Pathogenic TSC1 alleles are individually rare and generally absent or at extremely low frequency in gnomAD. A population frequency incompatible with this rare, highly penetrant disorder argues against pathogenicity.
• Germline, constitutional mosaic, and tissue-restricted somatic variants occur. Germline variants permit vertical transmission; mosaic variants may be missed in blood and still involve gonads.

A 2024 Brazilian molecular study detected pathogenic TSC1/TSC2 alterations in 106/116 (91%) clinically definite cases: 18 TSC1 (17%) and 88 TSC2 (83%); 35 were novel. Its abstract states: “Functional assessment can help establish variant pathogenicity and is a useful adjunct to DNA analysis.” (dufneralmeida2024molecularandfunctional pages 1-2)

Variant classification

Classification should follow ACMG/AMP criteria with TSC-specific evidence: predicted null consequence, segregation/de novo status, rarity, RNA evidence, copy-number evidence, and validated functional demonstration of impaired TSC complex suppression of mTORC1. A VUS is not a molecular diagnostic criterion. Functional assays are particularly valuable for missense, in-frame, and splice-region changes. (rosengren2020mutationalanalysisof pages 8-9, dufneralmeida2024molecularandfunctional pages 1-2)

Mosaicism, chromosomal abnormalities, and epigenetics

Conventional testing is negative in 10–15% of clinically definite cases. High-depth sequencing can uncover mosaic variants; RNA analysis can identify deep-intronic splice defects. A negative blood test does not exclude TSC. Mosaic cases average fewer features, but can develop any manifestation and can transmit a non-mosaic variant. (man2024thegeneticsof pages 1-2, man2024thegeneticsof pages 8-9, northrup2021updatedinternationaltuberous pages 10-14)

Large TSC1 deletions are uncommon but detectable by deletion/duplication analysis. Karyotyping has low yield. Unlike the TSC2/PKD1 contiguous-gene deletion syndrome at 16p13.3, there is no common TSC1 contiguous-gene syndrome. No validated disease-defining methylation episignature or epigenetic test is in routine use; reported chromatin changes are mainly downstream of altered metabolism/mTOR signaling.

5. Environmental information

TSC1-related TSC is not infectious or environmentally acquired and has no zoonotic or transmissible component. No causal bacteria, virus, fungus, parasite, radiation, occupational exposure, alcohol exposure, dietary pattern, or pollutant has been established. Clinically relevant modifiers include tobacco exposure in pulmonary disease, estrogen/pregnancy in LAM and AML, seizure precipitants, and drug–drug interactions during mTOR inhibition. The guideline specifically directs clinicians to inquire about tobacco exposure and pulmonary symptoms in adults. (northrup2021updatedinternationaltuberous pages 40-43)

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: germline or mosaic TSC1 loss-of-function variant.
2. Protein-complex defect: reduced/unstable hamartin compromises TSC1–TSC2–TBC1D7 complex activity.
3. Small-GTPase signaling: inadequate TSC2 GAP activity leaves RHEB predominantly GTP-bound.
4. Core pathway: constitutive lysosome-associated mTORC1 activation.
5. Downstream processes: increased S6K/4E-BP-dependent translation, ribosome and lipid/nucleotide biosynthesis, cellular hypertrophy/proliferation; suppression of autophagy and lysosome biogenesis; feedback inhibition of PI3K–AKT; altered mitochondrial, synaptic, and myelination programs.
6. Cell/tissue outcomes: dysplastic/cytomegalic neurons, reactive astrocytes, abnormal neuronal migration and connectivity, impaired oligodendrocyte maturation, smooth-muscle-like PEComas/AML and LAM cells, and hamartoma formation.
7. Clinical outcomes: epilepsy/TAND, SEGA, renal AML/CKD/hemorrhage, skin lesions, cardiac rhabdomyoma, and pulmonary LAM. (zucco2018thegenerationand pages 35-40, dufneralmeida2024molecularandfunctional pages 1-2, sørensen2024singlecellprofilingof pages 1-3, zimmer2020tuberoussclerosiscomplex pages 6-7)

Suggested GO terms include negative regulation of TORC1 signaling, regulation of small GTPase-mediated signal transduction, negative regulation of cell growth, macroautophagy, neuron migration, synapse organization, gliogenesis, myelination, mitochondrial respiration, fatty-acid metabolic process, and blood–brain barrier maintenance. Relevant compartments are lysosomal membrane, lysosome, cytosol, TSC complex, and mTORC1 complex.

Cellular and immune/tissue mechanisms

Neurons exhibit altered maturation, axonal/dendritic growth, excitability, AMPA signaling, and synaptic plasticity. Astrocyte Tsc1 deletion in mice causes astrogliosis and seizures, demonstrating non-neuronal causality. Oligodendrocyte/NG2-glia effects include abnormal maturation and hypomyelination. Microglial and cytokine activation is observed downstream in epileptogenic tissue, but TSC is not primarily autoimmune or immunodeficient. Renal and pulmonary lesions can undergo vascular remodeling, cystic destruction, hemorrhage, fibrosis, and loss of organ function. (zucco2018thegenerationand pages 40-44, zimmer2020tuberoussclerosiscomplex pages 6-7)

Suggested CL terms: glutamatergic neuron, GABAergic interneuron, astrocyte, oligodendrocyte, oligodendrocyte precursor/NG2 glial cell, microglial cell, endothelial cell, vascular smooth-muscle cell, renal epithelial cell, and pulmonary lymphangioleiomyomatosis cell.

Molecular profiling and advanced technologies

A 2024 single-nucleus RNA-seq preprint of resected cortical tubers found that, despite disrupted lamination, virtually all neuronal subtypes and layer-associated transcriptional identities were retained. Principal neurons and layer 1–2 GABAergic neurons had the largest expression changes. Neuronal—but not glial—networks showed reduced mitochondrial respiration and a switch toward fatty-acid metabolism; neuron-specific AMPA-receptor signaling was nominated as an epileptogenic target. The authors’ abstract states: “TSC neuronal, but not glial, networks exhibited massive metabolic reorganization with a reduction in mitochondrial respiration and a concomitant switch to fatty acid metabolism.” This is important but remains non-peer-reviewed. (Sørensen et al., posted 31 October 2024; DOI: https://doi.org/10.1101/2024.10.31.621014). (sørensen2024singlecellprofilingof pages 1-3)

A peer-reviewed 2024 iPSC/microfluidic neurovascular-unit study found increased permeability in a TSC2-mutant BBB model, rescued by wild-type astrocytes or rapamycin. Although TSC2-based, it supports a shared mTOR-dependent neurovascular mechanism relevant to TSC1. Its abstract states: “This can be rescued by wild type astrocytes or by treatment with rapamycin.” (Brown et al., May 2024; DOI: https://doi.org/10.1186/s11689-024-09543-y). (brown2024rescueofimpaired pages 1-2)

No metabolomic, lipidomic, spatial-transcriptomic, or circulating biomarker signature is yet validated for clinical diagnosis or prognosis. Single-cell data are mechanistically promising but not diagnostic.

7. Anatomical structures affected

• Brain: cerebral cortex/cortical tubers, subcortical white matter/radial migration lines, subependymal zone/SEN, foramen of Monro/SEGA. UBERON suggestions: brain, cerebral cortex, cerebral white matter, lateral ventricle, subependymal zone.
• Kidneys: bilateral renal cortex/medulla and vasculature, with AML and cysts. UBERON: kidney, renal cortex, renal medulla.
• Skin and appendages: facial dermis, lumbosacral connective tissue, periungual tissue. UBERON: skin of face, nail, dermis.
• Heart: ventricular myocardium, usually prenatal rhabdomyoma. UBERON: heart, myocardium.
• Lung/lymphatics: diffuse bilateral lung parenchyma in LAM and pulmonary nodules in MMPH. UBERON: lung, lung parenchyma, lymphatic vessel.
• Eye: retina and optic disc. UBERON: retina.
• Oral cavity and skeleton: enamel, gingiva, sclerotic axial bone lesions.

Renal lesions are commonly bilateral; LAM is diffuse bilateral; brain lesions are multifocal and asymmetric rather than predictably lateralized.

8. Temporal development

TSC is lifelong and biologically begins prenatally. Cardiac rhabdomyomas may be detected in fetal life; hypomelanotic macules and cortical lesions are congenital. Epileptiform EEG abnormalities and seizures commonly emerge in the first two years, a critical window for neurodevelopment. Facial angiofibromas and neuropsychiatric manifestations evolve through childhood. SEGA risk is greatest in childhood through young adulthood. Renal AML burden rises through adolescence/adulthood, with TOSCA showing a peak of new AMLs at 18–40 years. LAM is primarily adult and female-predominant. (kingswood2020renalmanifestationsof pages 1-2, northrup2021updatedinternationaltuberous pages 10-14, northrup2021updatedinternationaltuberous pages 40-43)

The course is chronic and variable, combining stable congenital lesions, episodic seizures, and slowly progressive tumors/organ dysfunction. Cardiac rhabdomyomas often regress spontaneously; AML, SEGA, and angiofibromas frequently regress during mTOR inhibition but can regrow after withdrawal. There is no conventional disease staging system or spontaneous systemic remission.

9. Inheritance and population

Inheritance is autosomal dominant. Penetrance is high/near-complete with age, but expressivity ranges from subclinical adult disease to severe infantile epilepsy and multiorgan involvement. Each child of an individual with a constitutional heterozygous variant has a 50% transmission risk. Mosaic parental transmission risk is below 50% but cannot be inferred reliably from blood VAF because gonadal involvement may differ. Apparent unaffected parents can have low-level somatic/gonadal mosaicism. Anticipation is not established; consanguinity is not etiologically relevant; a “carrier” generally has the disorder because this is dominant. (man2024thegeneticsof pages 1-2, man2024thegeneticsof pages 8-9, northrup2021updatedinternationaltuberous pages 10-14)

Overall incidence is approximately 1 per 6,000–10,000 live births, with recent reviews spanning 1:5,800–1:13,520. No robust ethnic or geographic predilection exists; differences mainly reflect ascertainment. Both sexes inherit TSC equally, although renal AML severity and LAM are female-predominant. (man2024thegeneticsof pages 1-2, jansen2020burdenofillness pages 1-2, kingswood2020renalmanifestationsof pages 1-2)

10. Diagnostics

Diagnostic criteria

A definite molecular diagnosis is established by a pathogenic TSC1 or TSC2 variant in normal tissue. A VUS is insufficient. A definite clinical diagnosis requires two major features or one major plus at least two minor features; possible TSC requires one major feature or at least two minor features. The 2021 criteria comprise 11 major and seven minor features, with “multiple cortical tubers and/or radial migration lines” replacing nonspecific “cortical dysplasia” and sclerotic bone lesions restored as a minor criterion. (northrup2021updatedinternationaltuberous pages 10-14, man2024thegeneticsof pages 8-9)

Major features include hypomelanotic macules, angiofibromas or fibrous cephalic plaque, ungual fibromas, shagreen patch, multiple retinal hamartomas, multiple cortical tubers/radial migration lines, subependymal nodules, SEGA, cardiac rhabdomyoma, LAM, and at least two renal AMLs. LAM plus AML alone is not sufficient for definite clinical diagnosis because both can co-occur in sporadic LAM.

Baseline clinical tests

At diagnosis: brain MRI; awake/sleep EEG and prolonged video-EEG if needed; abdominal MRI, blood pressure, and GFR; dermatologic, dental, and dilated ophthalmic examination; ECG at all ages and echocardiography in pediatric patients; chest CT in adult females and symptomatic adult males, followed by PFT/6-minute walk testing if cystic disease is present. MRI is preferred for renal imaging because 25–30% of AMLs are fat-poor and may be missed by ultrasound. (northrup2021updatedinternationaltuberous pages 10-14, northrup2021updatedinternationaltuberous pages 40-43)

Genetic testing pathway

1. Parallel sequencing of TSC1 and TSC2, preferably on an NGS panel with high read depth.
2. Exon-level and whole-gene deletion/duplication analysis, such as validated NGS-CNV calling plus MLPA.
3. If negative with strong clinical suspicion: ultra-deep sequencing of blood and a second tissue such as saliva/buccal cells; affected-tissue sequencing when ethically available; genome sequencing for intronic/structural variants; RNA studies for splice effects.
4. Targeted familial-variant testing for relatives, prenatal diagnosis, or preimplantation testing once a familial variant is known.

WES can detect coding variants but may miss mosaic, intronic, and structural alterations. WGS improves noncoding/structural detection but still requires adequate depth and mosaic-aware analysis. CMA is useful mainly for large deletions; karyotype and FISH have little routine utility. Mitochondrial and repeat-expansion tests are not indicated. Current molecular methods identify a causal alteration in nearly 90% of definite TSC; the 2024 Brazilian study reached 91%. (dufneralmeida2024molecularandfunctional pages 1-2, northrup2021updatedinternationaltuberous pages 10-14)

Differential diagnosis

Important alternatives include isolated cardiac rhabdomyoma, focal cortical dysplasia and other mTORopathies (DEPDC5/NPRL2/NPRL3, MTOR, RHEB, AKT3, PIK3CA, PTEN), Birt–Hogg–Dubé syndrome, neurofibromatosis, MEN1, sporadic LAM, sporadic AML/PEComa, polycystic kidney disease, and hypomelanosis of Ito. Distribution of characteristic skin findings, SEN/SEGA, multiple tubers/radial bands, bilateral AML, and molecular testing distinguish TSC.

Surveillance

• Brain MRI every 1–3 years in asymptomatic patients younger than 25; more frequently for growing SEGA.
• EEG every six weeks through 12 months and every three months through 24 months in asymptomatic infants; thereafter based on clinical need.
• Abdominal MRI every 1–3 years lifelong; blood pressure and renal function at least annually.
• Annual TAND screen; formal assessments at infancy, preschool, school entry, adolescence, and early adulthood.
• Baseline CT at ≥18 years in females and symptomatic males; repeat CT/PFT according to LAM findings.
• Pediatric echo every 1–3 years until regression is established; ECG every 3–5 years.
• Annual skin and ophthalmic review; dental examination every six months. (northrup2021updatedinternationaltuberous pages 40-43, northrup2021updatedinternationaltuberous pages 43-45)

11. Outcomes and prognosis

No single genotype-specific five- or ten-year survival estimate is sufficiently robust. Survival is often near normal in mildly affected TSC1 disease, but population mortality exceeds that of the general population. Major causes include epilepsy/SUDEP, SEGA complications, renal hemorrhage/CKD, and pulmonary LAM. Neurologic disability is driven especially by early seizure onset, refractory epilepsy, tuber burden, and TAND. Renal risk rises with AML size/growth, hypertension, repeated embolization/nephrectomy, and cystic disease. Pulmonary prognosis depends on FEV1/DLCO decline, pneumothorax, and chylous complications.

Current surveillance and pre-emptive therapy have improved prognosis. In TOSCA’s renal substudy, no patient bled after starting an mTOR inhibitor, although the sample was too small for definitive comparative inference. (kingswood2020renalmanifestationsof pages 1-2)

Recovery is manifestation-specific: seizures can remit, cardiac tumors regress, and mTOR inhibitors shrink tumors, but the underlying germline disorder persists. Established intellectual disability or chronic organ damage is incompletely reversible.

12. Treatment

Epilepsy and neurodevelopment

• Vigabatrin is first-line for TSC infantile spasms; if full-dose treatment fails after two weeks, ACTH, synthetic ACTH, or prednisolone is recommended. Serial ophthalmic monitoring is used because of retinal/visual-field toxicity. MAXO: antiseizure pharmacotherapy; ophthalmic monitoring. (northrup2021updatedinternationaltuberous pages 30-34, northrup2021updatedinternationaltuberous pages 40-43)
• Other seizure types receive syndrome-appropriate antiseizure drugs. A purified cannabidiol formulation and everolimus are approved for TSC-associated seizures. Ketogenic diet, vagus-nerve stimulation, and other neuromodulation are options in selected refractory cases.
• Epilepsy surgery should be evaluated after failure of approximately three appropriate medications, particularly with focal seizures and developmental regression, at an experienced TSC center. MAXO: resective epilepsy surgery, video-EEG monitoring, ketogenic dietary therapy. (northrup2021updatedinternationaltuberous pages 40-43)
• Behavioral, educational, speech/language, occupational, psychiatric, and sleep interventions should be tailored to the individual TAND profile; mTOR inhibitors are not established general TAND therapy.

mTOR-targeted therapy

Everolimus is used for growing SEGA not requiring immediate surgery, asymptomatic growing renal AML >3 cm, and refractory focal-onset TSC seizures. Sirolimus is used particularly for clinically significant LAM and in some jurisdictions/indications. These are disease-pathway-directed but suppress rather than permanently correct mTOR activation.

EXIST trials reported ≥50% volume reduction in 35% of SEGA and 42% of renal AML recipients. In EXIST-3, ≥50% seizure reduction occurred in 28% at low exposure and 40% at high exposure. (cockerell2023effectivenessandsafety pages 1-2)

In a 2023 Norway/Denmark real-world series of 64 patients, 31% of 45 epilepsy patients achieved ≥50% seizure reduction; response was 46% in patients under 18 versus 14% in adults. Among 29 AML patients, 38% had ≥30% diameter reduction and 59% were stable after a mean 37 months. Three SEGAs shrank 71%, 43%, and 48%. Adverse events affected 95%; stomatitis/oral ulceration occurred in 63%, upper-respiratory infection in 38%, hypercholesterolemia in 41%, anemia in 30%, leukopenia in 25%, and grade 3–4 events in 36%. The abstract concludes: “Close follow-up is needed for this group, especially for children and patients who may not be able to report adverse effects.” (published December 2023; DOI: https://doi.org/10.1186/s13023-023-02982-1). (cockerell2023effectivenessandsafety pages 1-2)

Monitor CBC, renal/liver chemistry, fasting lipids/glucose, urine protein, infection, stomatitis, pulmonary symptoms, menstrual/ovarian effects, vaccination status, wound healing, and CYP3A/P-gp interactions. MAXO: mTOR-inhibitor therapy, therapeutic drug monitoring, laboratory surveillance. CHEBI entities: everolimus and sirolimus/rapamycin.

Organ-specific procedures

• SEGA: urgent surgical resection for acute symptomatic obstruction/hydrocephalus; mTOR inhibitor or surgery for growing asymptomatic tumors; CSF diversion if necessary.
• Renal AML: mTOR inhibitor first-line for asymptomatic growing AML >3 cm; selective arterial embolization plus corticosteroids for acute hemorrhage. Avoid nephrectomy whenever possible. MAXO: arterial embolization, nephron-sparing surgery.
• LAM: sirolimus/everolimus for FEV1 <70% predicted, abnormal DLCO, air trapping/desaturation, rapid decline, or problematic chylous disease; pleural intervention for recurrent pneumothorax; transplant for end-stage disease. (northrup2021updatedinternationaltuberous pages 43-45)
• Skin: topical sirolimus, laser, or surgery for angiofibromas; surgery/laser for symptomatic fibromas. The completed phase 3 NPC-12Y study tested 0.2% topical sirolimus gel twice daily in 43 participants. (NCT05495425 chunk 1)
• Cardiac: observation for regressing asymptomatic rhabdomyoma; antiarrhythmic or surgical/mTOR-directed therapy for severe obstruction or refractory arrhythmia.

No CPIC/PharmGKB genotype-guided regimen specific to TSC1 is established. Treatment is phenotype- and pharmacokinetic-guided rather than TSC1-variant-guided.

Recent and ongoing trials

• NCT05104983 (TSC-STEPS): phase 2, randomized, triple-blind sirolimus prevention trial in 64 seizure-free infants aged ≤6 months; primary outcome is time to seizure onset by 12 months. (NCT05104983 chunk 1)
• NCT05534672 (RaRE-TS): phase 3 randomized double-blind rapamycin versus placebo for drug-resistant TSC epilepsy, estimated n=200. (NCT05534672 chunk 1)
• NCT02962414: active long-term open-label everolimus safety rollover from EXIST-3, n=206, with follow-up approaching ten years. (NCT02962414 chunk 1)
• NCT05323734 (TrustTSC): completed phase 3 ganaxolone trial, n=129, in TSC-related epilepsy; results were first posted in 2025 and therefore were not available as a 2024 peer-reviewed outcome in the retrieved evidence. (NCT05323734 chunk 1)
• NCT05059327: completed phase 2 crossover study of the mGluR5 inhibitor basimglurant, n=61. (NCT05059327 chunk 1)
• NCT05495425: completed phase 3 topical sirolimus-gel study, n=43. (NCT05495425 chunk 1)

Gene replacement, CRISPR editing, ASO/siRNA, and cell therapy remain preclinical; no approved treatment corrects the TSC1 allele.

13. Prevention

Primary prevention

There is no vaccine, lifestyle intervention, or medication that prevents a de novo TSC1 mutation. Reproductive options following molecular diagnosis include genetic counseling, targeted prenatal diagnosis, and IVF with preimplantation genetic testing. Because expressivity is unpredictable, genotype establishes risk but does not accurately predict severity.

Secondary prevention

Cascade testing identifies mildly affected relatives. Fetal echocardiography can detect rhabdomyoma. Population newborn screening is not routine, but infants identified prenatally or through family testing should enter immediate MRI/EEG surveillance. Early control of electrographic and clinical seizures is a major prevention target. The guideline notes that pre-emptive vigabatrin may delay seizure onset in infants with epileptiform EEG, although evidence that it improves long-term neurodevelopment beyond very early treatment of clinical seizures is mixed. (northrup2021updatedinternationaltuberous pages 10-14)

Tertiary prevention

Lifelong MRI, EEG, renal, pulmonary, cardiac, skin, eye, dental, and TAND surveillance seeks to prevent hydrocephalus, status epilepticus/SUDEP, renal hemorrhage/CKD, pneumothorax/respiratory failure, and avoidable disability. Smoking avoidance, blood-pressure control, renal preservation, infection prevention during immunosuppression, and treatment adherence are practical measures.

14. Other species and natural disease

Orthologous Tsc1 genes are highly conserved in mammals and other metazoans. Key taxa include human NCBI Taxon 9606, mouse 10090, rat 10116, zebrafish 7955, and Drosophila 7227. No well-established, prevalent naturally occurring veterinary syndrome equivalent to human germline TSC1-related multisystem TSC was identified in the retrieved evidence. Sporadic hamartomas in animals should not be assumed to constitute inherited TSC. The condition is noninfectious, non-zoonotic, and cannot transmit across species.

Conservation of the TSC–RHEB–mTOR axis supports comparative experiments, but organ spectrum, cortical architecture, lifespan, and requirement for second hits differ across species.

15. Model organisms and experimental systems

• Conditional Tsc1 mice: GFAP-Cre models reproduce astrogliosis, neuronal disorganization, seizures, and premature death; neuron-specific knockouts model hypertrophy, altered excitability, synaptic defects, and abnormal neuron–oligodendrocyte signaling; oligodendrocyte-lineage deletion perturbs myelination. These demonstrate cell-autonomous and non-cell-autonomous mechanisms and rapamycin responsiveness. Limitations include severe engineered biallelic loss and mouse–human cortical differences. (zucco2018thegenerationand pages 40-44, zimmer2020tuberoussclerosiscomplex pages 6-7)
• Tsc1 heterozygous mice: useful for learning, social behavior, synaptic plasticity, and haploinsufficiency, but generally do not reproduce the full human tumor burden.
• Eker rat (Tsc2): landmark spontaneous tumor model validating second-hit/LOH biology, especially renal tumors. It is mechanistically relevant to TSC1 but is not a Tsc1 model. (zucco2018thegenerationand pages 40-44)
• Zebrafish and Drosophila: permit rapid developmental, growth, neuronal, and modifier/drug screens. Their conserved TOR signaling is a strength; absence of a human-like cortex and incomplete multiorgan pathology are major limitations. (brown2024rescueofimpaired pages 1-2)
• MEFs and engineered cell lines: quantify p-S6K/p-S6/4E-BP1, complex stability, and RHEB/mTORC1 suppression for variant classification and drug screening. They lack tissue architecture.
• Patient-derived iPSC neurons, astrocytes, oligodendrocytes, cardiomyocytes, and organoids: preserve human genetic background and model lineage-specific differentiation, excitability, myelination, and mTOR dependence. Organoids add developmental cellular diversity but lack mature vasculature, immune integration, and lifelong organ interactions.
• Microfluidic neurovascular-unit chips: the 2024 BBB study showed TSC-mutant barrier leak rescued by wild-type astrocytes or rapamycin, offering a platform for lineage dissection and pharmacologic testing. (brown2024rescueofimpaired pages 1-2)
• Resected human tubers with single-nucleus/spatial methods: highest direct human relevance for cell-type states and epileptogenic networks, but confounded by end-stage disease, antiseizure treatment, surgery selection, and limited normal pediatric controls. The 2024 single-cell study explicitly cautioned that animal and iPSC-neuron models cannot fully reproduce human cortical neuronal complexity. (sørensen2024singlecellprofilingof pages 1-3)

Overall expert assessment

TSC1-related TSC is best understood as a developmental mosaic tumor-suppressor disorder and canonical mTORopathy, not merely a collection of benign tumors. TSC1 generally predicts a milder average phenotype than TSC2, but individual management must never be relaxed on genotype alone: mosaic TSC1 can be clinically subtle, conventional blood testing can be negative, and severe neurologic, renal, or pulmonary disease remains possible. The strongest current real-world implementation is coordinated lifelong multidisciplinary surveillance coupled to early epilepsy treatment and lesion-directed mTOR inhibition. The most important 2023–2024 developments are higher-yield molecular diagnosis with functional variant assessment, genotype/mosaicism-aware sequencing, real-world long-term mTOR-inhibitor safety data, preventive sirolimus trials in infants, and single-cell evidence that metabolic and neuron-specific circuit remodeling—not simple loss of neuronal identity—may underlie cortical-tuber epileptogenesis. (dufneralmeida2024molecularandfunctional pages 1-2, sørensen2024singlecellprofilingof pages 1-3, cockerell2023effectivenessandsafety pages 1-2, man2024thegeneticsof pages 8-9, NCT05104983 chunk 1)

References

1. (OpenTargets Search: tuberous sclerosis 1,tuberous sclerosis complex-TSC1): Open Targets Query (tuberous sclerosis 1,tuberous sclerosis complex-TSC1, 8 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (man2024thegeneticsof pages 1-2): Alice Man, Matteo Di Scipio, Shan Grewal, Yujin Suk, Elisabetta Trinari, Resham Ejaz, and Robyn Whitney. The genetics of tuberous sclerosis complex and related mtoropathies: current understanding and future directions. Genes, 15:332, Mar 2024. URL: https://doi.org/10.3390/genes15030332, doi:10.3390/genes15030332. This article has 52 citations.

3. (dufneralmeida2024molecularandfunctional pages 1-2): Luiz Gustavo Dufner-Almeida, Laís F. M. Cardozo, Mariana R. Schwind, Danielly Carvalho, Juliana Paula G. Almeida, Andrea Maria Cappellano, Thiago G. P. Alegria, Santoesha Nanhoe, Mark Nellist, Maria Rita Passos-Bueno, Silvana Chiavegatto, Nasjla S. Silva, Sérgio Rosemberg, Ana Paula A. Pereira, Sérgio Antônio Antoniuk, and Luciana A. Haddad. Molecular and functional assessment of tsc1 and tsc2 in individuals with tuberous sclerosis complex. Genes, 15:1432, Nov 2024. URL: https://doi.org/10.3390/genes15111432, doi:10.3390/genes15111432. This article has 11 citations.

4. (northrup2021updatedinternationaltuberous pages 10-14): Hope Northrup, Mary E. Aronow, E. Martina Bebin, John Bissler, Thomas N. Darling, Petrus J. de Vries, Michael D. Frost, Zoë Fuchs, Elizabeth S. Gosnell, Nishant Gupta, Anna C. Jansen, Sergiusz Jóźwiak, J. Chris Kingswood, Timothy K. Knilans, Francis X. McCormack, Ashley Pounders, Steven L. Roberds, David F. Rodriguez-Buritica, Jonathan Roth, Julian R. Sampson, Steven Sparagana, Elizabeth Anne Thiele, Howard L. Weiner, James W. Wheless, Alexander J. Towbin, Darcy A. Krueger, Nicholas M.P. Annear, Mary E. Aronow, Ute Bartels, E. Martina Bebin, Moncef Berhouma, John J. Bissler, Klemens Budde, Anna Byars, Harry Chugani, Edward W. Cowen, Peter B. Crino, Paolo Curatolo, Thomas N. Darling, Petrus de Vries, Daniel F. Dilling, David W. Dunn, Rosmary Ekong, Kevin C. Ess, David N. Franz, Michael Frost, Zoë D.B. Fuchs, Elizabeth Gosnell, Lisa Guay-Woodford, Nishant Gupta, Luciana Haddad, Anne Halbert, Adelaide A. Hebert, Elizabeth P. Henske, Gregory L. Holmes, Dena Hook, John Hulbert, Anna Jansen, Simon R. Johnson, Sergiusz Jóźwiak, Bryan King, J. Christopher Kingswood, Timothy K. Knilans, Mary Kay Koenig, Bruce Korf, Darcy A. Krueger, David J. Kwiatkowski, Francis X. McCormack, Joel Moss, David Mowat, Kate Mowrey, Rima Nabbout, Mark D. Nellist, Hope Northrup, Finbar O'Callaghan, Uday Patel, Ashley Pounders, E. Steve Roach, Steven L. Roberds, David Rodriguez-Buritica, Robb Romp, Jonathan Roth, Micaela Rozenberg, Stephen J. Ruoss, Mustafa Sahin, Julian Sampson, Joshua A. Samuels, Matthias Sauter, Catherine A. Smith, Keyomaurs Soltani, Steven Sparagana, Shoba Srivastava, Clare Stuart, Joyce M.C. Teng, Elizabeth A. Thiele, Alexander J. Towbin, Andrew Trout, Agnies van Eeghen, Stephanie Vanclooster, Henry Z. Wang, Mari Wataya-Kaneda, Howard L. Weiner, James W. Wheless, Patricia Witman, Tim Wright, Joyce Y. Wu, and Lisa Young. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123:50-66, Oct 2021. URL: https://doi.org/10.1016/j.pediatrneurol.2021.07.011, doi:10.1016/j.pediatrneurol.2021.07.011. This article has 832 citations and is from a peer-reviewed journal.

5. (jansen2020burdenofillness pages 1-2): Anna C. Jansen, Stephanie Vanclooster, Petrus J. de Vries, Carla Fladrowski, Guillaume Beaure d'Augères, Tom Carter, Elena Belousova, Mirjana P. Benedik, Vincent Cottin, Paolo Curatolo, Maria Dahlin, Lisa D'Amato, José C. Ferreira, Martha Feucht, Christoph Hertzberg, Sergiusz Jozwiak, John A. Lawson, Alfons Macaya, Ruben Marques, Rima Nabbout, Finbar O'Callaghan, Jiong Qin, Valentin Sander, Matthias Sauter, Seema Shah, Yukitoshi Takahashi, Renaud Touraine, Sotiris Youroukos, Bernard Zonnenberg, and J. Chris Kingswood. Burden of illness and quality of life in tuberous sclerosis complex: findings from the tosca study. Frontiers in Neurology, Aug 2020. URL: https://doi.org/10.3389/fneur.2020.00904, doi:10.3389/fneur.2020.00904. This article has 50 citations and is from a peer-reviewed journal.

6. (man2024thegeneticsof pages 8-9): Alice Man, Matteo Di Scipio, Shan Grewal, Yujin Suk, Elisabetta Trinari, Resham Ejaz, and Robyn Whitney. The genetics of tuberous sclerosis complex and related mtoropathies: current understanding and future directions. Genes, 15:332, Mar 2024. URL: https://doi.org/10.3390/genes15030332, doi:10.3390/genes15030332. This article has 52 citations.

7. (pratico2025geneticscreeningof pages 3-4): Andrea Domenico Praticò, Claudia Di Napoli, Stefania Salafia, Edoardo Dammino, Maria Piccione, Francesco Calì, Renato Scifo, Michele Vecchio, Andrea Zonta, Maria Bonsignore, Maurizio Elia, Manuela Lo Bianco, Agata Polizzi, and Martino Ruggieri. Genetic screening of tuberous sclerosis complex in sicily with a focus on neurological manifestations. Scientific Reports, Jun 2025. URL: https://doi.org/10.1038/s41598-025-04718-6, doi:10.1038/s41598-025-04718-6. This article has 3 citations and is from a peer-reviewed journal.

8. (singh2023treatmentresistantepilepsyand pages 1-3): Avantika Singh, Aristides Hadjinicolaou, Jurriaan M Peters, and Catherine L Salussolia. Treatment-resistant epilepsy and tuberous sclerosis complex: treatment, maintenance, and future directions. Neuropsychiatric Disease and Treatment, 19:733-748, Apr 2023. URL: https://doi.org/10.2147/ndt.s347327, doi:10.2147/ndt.s347327. This article has 23 citations and is from a peer-reviewed journal.

9. (kingswood2020renalmanifestationsof pages 1-2): J. Chris Kingswood, Elena Belousova, Mirjana P. Benedik, Tom Carter, Vincent Cottin, Paolo Curatolo, Maria Dahlin, Lisa D'Amato, Guillaume Beaure d'Augères, Petrus J. de Vries, José C. Ferreira, Martha Feucht, Carla Fladrowski, Christoph Hertzberg, Sergiusz Jozwiak, John A. Lawson, Alfons Macaya, Ruben Marques, Rima Nabbout, Finbar O'Callaghan, Jiong Qin, Valentin Sander, Seema Shah, Yukitoshi Takahashi, Renaud Touraine, Sotiris Youroukos, Bernard Zonnenberg, Anna C. Jansen, and Matthias Sauter. Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the tosca study focussing mainly on renal angiomyolipomas. Frontiers in Neurology, Sep 2020. URL: https://doi.org/10.3389/fneur.2020.00972, doi:10.3389/fneur.2020.00972. This article has 75 citations and is from a peer-reviewed journal.

10. (NCT05495425 chunk 1): Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC. Nobelpharma. 2022. ClinicalTrials.gov Identifier: NCT05495425

11. (zucco2018thegenerationand pages 35-40): Avery J. Zucco. The generation and characterization of a human induced pluripotent stem cell model for the tuberous sclerosis complex. ArXiv, Jan 2018. URL: https://doi.org/10.7282/t3-9ahy-yx47, doi:10.7282/t3-9ahy-yx47. This article has 0 citations.

12. (sørensen2024singlecellprofilingof pages 1-3): Frederik Nørby Friis Sørensen, Tin Luka Petanjek, Mirte Scheper, Rasmus Rydbirk, Irina Korshunova, Jasper Anink, Angelika Mühlebner, James D. Mills, Zdravko Petanjek, Eleonora Aronica, and Konstantin Khodosevich. Single-cell profiling of cortical tubers in tuberous sclerosis complex shows molecular structure preservation and massive reorganization of metabolism. bioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.31.621014, doi:10.1101/2024.10.31.621014. This article has 4 citations.

13. (brown2024rescueofimpaired pages 1-2): Jacquelyn A. Brown, Shannon L. Faley, Monika Judge, Patricia Ward, Rebecca A. Ihrie, Robert Carson, Laura Armstrong, Mustafa Sahin, John P. Wikswo, Kevin C. Ess, and M. Diana Neely. Rescue of impaired blood-brain barrier in tuberous sclerosis complex patient derived neurovascular unit. Journal of Neurodevelopmental Disorders, May 2024. URL: https://doi.org/10.1186/s11689-024-09543-y, doi:10.1186/s11689-024-09543-y. This article has 4 citations and is from a peer-reviewed journal.

14. (zimmer2020tuberoussclerosiscomplex pages 6-7): Till S. Zimmer, Diede W. M. Broekaart, Victoria-Elisabeth Gruber, Erwin A. van Vliet, Angelika Mühlebner, and Eleonora Aronica. Tuberous sclerosis complex as disease model for investigating mtor-related gliopathy during epileptogenesis. Frontiers in Neurology, Sep 2020. URL: https://doi.org/10.3389/fneur.2020.01028, doi:10.3389/fneur.2020.01028. This article has 59 citations and is from a peer-reviewed journal.

15. (northrup2021updatedinternationaltuberous pages 40-43): Hope Northrup, Mary E. Aronow, E. Martina Bebin, John Bissler, Thomas N. Darling, Petrus J. de Vries, Michael D. Frost, Zoë Fuchs, Elizabeth S. Gosnell, Nishant Gupta, Anna C. Jansen, Sergiusz Jóźwiak, J. Chris Kingswood, Timothy K. Knilans, Francis X. McCormack, Ashley Pounders, Steven L. Roberds, David F. Rodriguez-Buritica, Jonathan Roth, Julian R. Sampson, Steven Sparagana, Elizabeth Anne Thiele, Howard L. Weiner, James W. Wheless, Alexander J. Towbin, Darcy A. Krueger, Nicholas M.P. Annear, Mary E. Aronow, Ute Bartels, E. Martina Bebin, Moncef Berhouma, John J. Bissler, Klemens Budde, Anna Byars, Harry Chugani, Edward W. Cowen, Peter B. Crino, Paolo Curatolo, Thomas N. Darling, Petrus de Vries, Daniel F. Dilling, David W. Dunn, Rosmary Ekong, Kevin C. Ess, David N. Franz, Michael Frost, Zoë D.B. Fuchs, Elizabeth Gosnell, Lisa Guay-Woodford, Nishant Gupta, Luciana Haddad, Anne Halbert, Adelaide A. Hebert, Elizabeth P. Henske, Gregory L. Holmes, Dena Hook, John Hulbert, Anna Jansen, Simon R. Johnson, Sergiusz Jóźwiak, Bryan King, J. Christopher Kingswood, Timothy K. Knilans, Mary Kay Koenig, Bruce Korf, Darcy A. Krueger, David J. Kwiatkowski, Francis X. McCormack, Joel Moss, David Mowat, Kate Mowrey, Rima Nabbout, Mark D. Nellist, Hope Northrup, Finbar O'Callaghan, Uday Patel, Ashley Pounders, E. Steve Roach, Steven L. Roberds, David Rodriguez-Buritica, Robb Romp, Jonathan Roth, Micaela Rozenberg, Stephen J. Ruoss, Mustafa Sahin, Julian Sampson, Joshua A. Samuels, Matthias Sauter, Catherine A. Smith, Keyomaurs Soltani, Steven Sparagana, Shoba Srivastava, Clare Stuart, Joyce M.C. Teng, Elizabeth A. Thiele, Alexander J. Towbin, Andrew Trout, Agnies van Eeghen, Stephanie Vanclooster, Henry Z. Wang, Mari Wataya-Kaneda, Howard L. Weiner, James W. Wheless, Patricia Witman, Tim Wright, Joyce Y. Wu, and Lisa Young. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123:50-66, Oct 2021. URL: https://doi.org/10.1016/j.pediatrneurol.2021.07.011, doi:10.1016/j.pediatrneurol.2021.07.011. This article has 832 citations and is from a peer-reviewed journal.

16. (northrup2021updatedinternationaltuberous pages 43-45): Hope Northrup, Mary E. Aronow, E. Martina Bebin, John Bissler, Thomas N. Darling, Petrus J. de Vries, Michael D. Frost, Zoë Fuchs, Elizabeth S. Gosnell, Nishant Gupta, Anna C. Jansen, Sergiusz Jóźwiak, J. Chris Kingswood, Timothy K. Knilans, Francis X. McCormack, Ashley Pounders, Steven L. Roberds, David F. Rodriguez-Buritica, Jonathan Roth, Julian R. Sampson, Steven Sparagana, Elizabeth Anne Thiele, Howard L. Weiner, James W. Wheless, Alexander J. Towbin, Darcy A. Krueger, Nicholas M.P. Annear, Mary E. Aronow, Ute Bartels, E. Martina Bebin, Moncef Berhouma, John J. Bissler, Klemens Budde, Anna Byars, Harry Chugani, Edward W. Cowen, Peter B. Crino, Paolo Curatolo, Thomas N. Darling, Petrus de Vries, Daniel F. Dilling, David W. Dunn, Rosmary Ekong, Kevin C. Ess, David N. Franz, Michael Frost, Zoë D.B. Fuchs, Elizabeth Gosnell, Lisa Guay-Woodford, Nishant Gupta, Luciana Haddad, Anne Halbert, Adelaide A. Hebert, Elizabeth P. Henske, Gregory L. Holmes, Dena Hook, John Hulbert, Anna Jansen, Simon R. Johnson, Sergiusz Jóźwiak, Bryan King, J. Christopher Kingswood, Timothy K. Knilans, Mary Kay Koenig, Bruce Korf, Darcy A. Krueger, David J. Kwiatkowski, Francis X. McCormack, Joel Moss, David Mowat, Kate Mowrey, Rima Nabbout, Mark D. Nellist, Hope Northrup, Finbar O'Callaghan, Uday Patel, Ashley Pounders, E. Steve Roach, Steven L. Roberds, David Rodriguez-Buritica, Robb Romp, Jonathan Roth, Micaela Rozenberg, Stephen J. Ruoss, Mustafa Sahin, Julian Sampson, Joshua A. Samuels, Matthias Sauter, Catherine A. Smith, Keyomaurs Soltani, Steven Sparagana, Shoba Srivastava, Clare Stuart, Joyce M.C. Teng, Elizabeth A. Thiele, Alexander J. Towbin, Andrew Trout, Agnies van Eeghen, Stephanie Vanclooster, Henry Z. Wang, Mari Wataya-Kaneda, Howard L. Weiner, James W. Wheless, Patricia Witman, Tim Wright, Joyce Y. Wu, and Lisa Young. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123:50-66, Oct 2021. URL: https://doi.org/10.1016/j.pediatrneurol.2021.07.011, doi:10.1016/j.pediatrneurol.2021.07.011. This article has 832 citations and is from a peer-reviewed journal.

17. (cockerell2023effectivenessandsafety pages 1-2): Ine Cockerell, Jakob Christensen, Christina E. Hoei-Hansen, Lotte Holst, Mikkel Grenaa Frederiksen, Aart Imran Issa-Epe, Bård Nedregaard, Ragnar Solhoff, Ketil Heimdal, Cecilie Johannessen Landmark, Caroline Lund, and Terje Nærland. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Orphanet Journal of Rare Diseases, Dec 2023. URL: https://doi.org/10.1186/s13023-023-02982-1, doi:10.1186/s13023-023-02982-1. This article has 29 citations and is from a peer-reviewed journal.

18. (NCT02962414 chunk 1): Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment. Novartis Pharmaceuticals. 2017. ClinicalTrials.gov Identifier: NCT02962414

19. (NCT05534672 chunk 1): Katarzyna Kotulska. Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex. Katarzyna Kotulska. 2023. ClinicalTrials.gov Identifier: NCT05534672

20. (NCT05104983 chunk 1): Darcy Krueger. Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study. Darcy Krueger. 2021. ClinicalTrials.gov Identifier: NCT05104983

21. (NCT05323734 chunk 1): Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy. Marinus Pharmaceuticals. 2022. ClinicalTrials.gov Identifier: NCT05323734

22. (NCT05059327 chunk 1): Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC. Noema Pharma AG. 2022. ClinicalTrials.gov Identifier: NCT05059327

23. (zucco2018thegenerationand pages 40-44): Avery J. Zucco. The generation and characterization of a human induced pluripotent stem cell model for the tuberous sclerosis complex. ArXiv, Jan 2018. URL: https://doi.org/10.7282/t3-9ahy-yx47, doi:10.7282/t3-9ahy-yx47. This article has 0 citations.

24. (pratico2025geneticscreeningof pages 8-9): Andrea Domenico Praticò, Claudia Di Napoli, Stefania Salafia, Edoardo Dammino, Maria Piccione, Francesco Calì, Renato Scifo, Michele Vecchio, Andrea Zonta, Maria Bonsignore, Maurizio Elia, Manuela Lo Bianco, Agata Polizzi, and Martino Ruggieri. Genetic screening of tuberous sclerosis complex in sicily with a focus on neurological manifestations. Scientific Reports, Jun 2025. URL: https://doi.org/10.1038/s41598-025-04718-6, doi:10.1038/s41598-025-04718-6. This article has 3 citations and is from a peer-reviewed journal.

25. (rosengren2020mutationalanalysisof pages 8-9): Thomas Rosengren, Santoesha Nanhoe, Luis Gustavo Dufner de Almeida, Bitten Schönewolf-Greulich, Lasse Jonsgaard Larsen, Caroline Amalie Brunbjerg Hey, Morten Dunø, Jakob Ek, Lotte Risom, Mark Nellist, and Lisbeth Birk Møller. Mutational analysis of tsc1 and tsc2 in danish patients with tuberous sclerosis complex. Scientific Reports, Jun 2020. URL: https://doi.org/10.1038/s41598-020-66588-4, doi:10.1038/s41598-020-66588-4. This article has 31 citations and is from a peer-reviewed journal.

26. (northrup2021updatedinternationaltuberous pages 30-34): Hope Northrup, Mary E. Aronow, E. Martina Bebin, John Bissler, Thomas N. Darling, Petrus J. de Vries, Michael D. Frost, Zoë Fuchs, Elizabeth S. Gosnell, Nishant Gupta, Anna C. Jansen, Sergiusz Jóźwiak, J. Chris Kingswood, Timothy K. Knilans, Francis X. McCormack, Ashley Pounders, Steven L. Roberds, David F. Rodriguez-Buritica, Jonathan Roth, Julian R. Sampson, Steven Sparagana, Elizabeth Anne Thiele, Howard L. Weiner, James W. Wheless, Alexander J. Towbin, Darcy A. Krueger, Nicholas M.P. Annear, Mary E. Aronow, Ute Bartels, E. Martina Bebin, Moncef Berhouma, John J. Bissler, Klemens Budde, Anna Byars, Harry Chugani, Edward W. Cowen, Peter B. Crino, Paolo Curatolo, Thomas N. Darling, Petrus de Vries, Daniel F. Dilling, David W. Dunn, Rosmary Ekong, Kevin C. Ess, David N. Franz, Michael Frost, Zoë D.B. Fuchs, Elizabeth Gosnell, Lisa Guay-Woodford, Nishant Gupta, Luciana Haddad, Anne Halbert, Adelaide A. Hebert, Elizabeth P. Henske, Gregory L. Holmes, Dena Hook, John Hulbert, Anna Jansen, Simon R. Johnson, Sergiusz Jóźwiak, Bryan King, J. Christopher Kingswood, Timothy K. Knilans, Mary Kay Koenig, Bruce Korf, Darcy A. Krueger, David J. Kwiatkowski, Francis X. McCormack, Joel Moss, David Mowat, Kate Mowrey, Rima Nabbout, Mark D. Nellist, Hope Northrup, Finbar O'Callaghan, Uday Patel, Ashley Pounders, E. Steve Roach, Steven L. Roberds, David Rodriguez-Buritica, Robb Romp, Jonathan Roth, Micaela Rozenberg, Stephen J. Ruoss, Mustafa Sahin, Julian Sampson, Joshua A. Samuels, Matthias Sauter, Catherine A. Smith, Keyomaurs Soltani, Steven Sparagana, Shoba Srivastava, Clare Stuart, Joyce M.C. Teng, Elizabeth A. Thiele, Alexander J. Towbin, Andrew Trout, Agnies van Eeghen, Stephanie Vanclooster, Henry Z. Wang, Mari Wataya-Kaneda, Howard L. Weiner, James W. Wheless, Patricia Witman, Tim Wright, Joyce Y. Wu, and Lisa Young. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123:50-66, Oct 2021. URL: https://doi.org/10.1016/j.pediatrneurol.2021.07.011, doi:10.1016/j.pediatrneurol.2021.07.011. This article has 832 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00